First, HER2. Now, HER3. That’s the plan of attack for BioNTech in its apparent bid to follow in the footsteps of antibody-drug conjugate leader Daiichi Sankyo.
After licensing a HER2-targeting ADC from DualityBio in April and taking the treatment candidate into Phase III this fall, BioNTech is now teaming up…
Click here to view original post
